{"product_id":"petv-vrio-analysis","title":"PetVivo Holdings, Inc. (PETV): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs PetVivo Holdings, Inc. (PETV) truly built to last? This VRIO analysis cuts straight to the core, dissecting whether its key resources are Valuable, Rare, Inimitable, and Organized to forge a sustainable competitive advantage. Discover the definitive answer to how PetVivo Holdings, Inc. (PETV) maintains its edge - dive in below to see the full strategic breakdown.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePetVivo Holdings, Inc. (PETV) - VRIO Analysis: 1. Proprietary Product Portfolio (Spryng and PrecisePRP)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core engine of PetVivo Holdings' current valuation - the proprietary products Spryng and PrecisePRP. Honestly, the near-term story here is about commercial execution on these two assets. If they can keep the sales momentum going, the competitive moat looks defensible for now.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Immediate Revenue and Clinical Utility\u003c\/h3\u003e\n\u003cp\u003eThese products deliver tangible value right now. Spryng with OsteoCushion Technology is a veterinarian-administered, intra-articular injection that mimics cartilage to restore joint mechanics, not just mask symptoms. The adoption is growing, with more than 12,000 animals treated across dogs and horses as of December 2025. PrecisePRP complements this by being an off-the-shelf, ready-to-inject regenerative option, saving vets time - no blood draw or centrifugation needed.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on the recent performance:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ2 fiscal 2026 revenue hit \u003cstrong\u003e$303,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThis represented a \u003cstrong\u003e51%\u003c\/strong\u003e year-over-year increase.\u003c\/li\u003e\n\u003cli\u003eDistributor sales accounted for \u003cstrong\u003e$237,000\u003c\/strong\u003e, or \u003cstrong\u003e75%\u003c\/strong\u003e of that revenue.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWhat this estimate hides is the gross margin pressure; it was \u003cstrong\u003e72.6%\u003c\/strong\u003e in Q2 2026, down from 89.5% a year prior, mainly due to the new PrecisePRP product mix.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: Unique Technology and Regulatory Status\u003c\/h3\u003e\n\u003cp\u003eThe rarity comes from two distinct angles. First, the OsteoCushion Technology in Spryng is based on proprietary biomaterial science, protected by a portfolio that includes twelve patents and six trade secrets. Second, PrecisePRP has a significant regulatory edge. It is noted as the only PRP therapy reviewed by the FDA for safety, specifically classified as an FDA reviewed Lower Risk Animal Cells, Tissues, and Cell- and Tissue-Based Product (ACTP).\u003c\/p\u003e\n\u003cp\u003eThe regulatory status is key:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFDA determined it does not expect an application for approval prior to marketing for the canine version.\u003c\/li\u003e\n\u003cli\u003eThis status sets it apart from competitors who lack this FDA review.\u003c\/li\u003e\n\u003cli\u003eThe product is shelf-stable, unlike many traditional PRP kits.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eImitability: Defensibility Through IP and Process\u003c\/h3\u003e\n\u003cp\u003eImitability is high because the core value is locked behind intellectual property and regulatory hurdles. The patented biomaterial science underpinning Spryng is not easily reverse-engineered. For PrecisePRP, the regulatory review process itself acts as a barrier to entry; competitors would need to replicate that multi-step, time-consuming FDA evaluation to claim parity on that specific safety assurance.\u003c\/p\u003e\n\u003cp\u003eIt’s defintely not easy to copy this combination. The company is organized to push these products, evidenced by increasing sales and marketing spend to drive the PrecisePRP rollout.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Strategic Focus and Sales Execution\u003c\/h3\u003e\n\u003cp\u003ePetVivo Holdings is clearly organizing its operations around these two products. Management is actively driving the sales mix toward them, which is why we see the revenue growth, even if it pressures the immediate gross margin percentage. The company is expanding its footprint, engaging additional distributors domestically and internationally, including the UK and Mexico, to support this push.\u003c\/p\u003e\n\u003cp\u003eThe VRIO scoring for this portfolio looks like this:\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eResource\/Capability\u003c\/th\u003e\n\u003cth\u003eValue (V)\u003c\/th\u003e\n\u003cth\u003eRarity (R)\u003c\/th\u003e\n\u003cth\u003eImitability (I)\u003c\/th\u003e\n\u003cth\u003eOrganization (O)\u003c\/th\u003e\n\u003cth\u003eCompetitive Implication\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpryng (OsteoCushion Tech)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eCostly to Imitate\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrecisePRP (FDA Reviewed Status)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eDifficult to Imitate\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eSustained Competitive Advantage (if maintained)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eCompetitive Advantage: Sustained Potential\u003c\/h3\u003e\n\u003cp\u003eThe current advantage leans toward \u003cstrong\u003eSustained Competitive Advantage\u003c\/strong\u003e, but it’s conditional. The patents must remain robust and actively defended. More critically, the regulatory advantage of PrecisePRP - being the only reviewed PRP product - must be maintained as competitors may seek similar reviews or the FDA guidance could shift. If the company can continue to scale adoption, as suggested by the \u003cstrong\u003e51%\u003c\/strong\u003e revenue jump in Q2 2026, this advantage becomes more entrenched.\u003c\/p\u003e\n\u003cp\u003eActionable Insight: Finance needs to model the cash burn against the operating loss of \u003cstrong\u003e$2.1 million\u003c\/strong\u003e (excluding debt discount) in Q2 2026 to ensure runway supports the continued sales and marketing investment required to cement this advantage.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePetVivo Holdings, Inc. (PETV) - VRIO Analysis: 2. Intellectual Property Estate (Patents and Trade Secrets)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA portfolio of \u003cstrong\u003etwelve patents\u003c\/strong\u003e and \u003cstrong\u003esix trade secrets\u003c\/strong\u003e protects the core biomaterials, production processes, and methods of use for their therapeutics.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTwelve patents\u003c\/strong\u003e offer a significant barrier to entry compared to smaller, non-IP-backed competitors in the animal health device space.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDifficult to imitate due to the time and cost required to legally challenge or replicate patented processes.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company structure supports commercialization, with a pipeline of \u003cstrong\u003eseventeen\u003c\/strong\u003e products for animal treatment. The company has received a series of grants totaling \u003cstrong\u003e$5.5M\u003c\/strong\u003e from the National Institutes of Health for development work. The structure requires R\u0026amp;D spending to maintain the pipeline, as evidenced by the following:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFiscal Period\u003c\/td\u003e\n\u003ctd\u003eResearch and Development (R\u0026amp;D) Expenses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFiscal 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1,583,250\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFiscal 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1,395,371\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe AI technology partnership includes \u003cstrong\u003efive patent-pending\u003c\/strong\u003e innovations.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained, as IP is the classic moat in medical technology.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe portfolio includes protection for the signature product, Spryng™ with OsteoCushion™ Technology.\u003c\/li\u003e\n\u003cli\u003eThe company has a strategy to pursue, capture, and enforce proprietary intellectual property assets.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePetVivo Holdings, Inc. (PETV) - VRIO Analysis: 3. Exclusive B2B Veterinary AI Licensing Agreement\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe agreement grants PetVivo exclusive 10-year B2B veterinary market rights to the Agentic Pet AI technology, which is projected to deliver a 90% - 98% reduction in client acquisition costs for veterinary practices, potentially dropping the cost from $80–$400 per client to $1.50 - $5.00 per targeted outreach.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe exclusivity for the integrated AgenticPet AI platform within the veterinary B2B channel is currently unique, secured via an exclusive 10-year white-label licensing agreement signed in October 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate imitability. The technology is protected by 5 patent-pending innovations and 9 specialized AI agents. Replicating the 10-year exclusivity period and the integrated platform timeline presents a significant barrier.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company is organized for immediate integration, with the dual-platform launch scheduled for Q1 2026. This follows reported 141% year-over-year growth in Q1 FY2026 on record fiscal 2025 revenue of $1.13 million.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe advantage is temporary, directly linked to the 10-year exclusivity period, which is set to expire in October 2035.\u003c\/p\u003e\n\n\u003cp\u003eKey quantitative metrics associated with the AI licensing agreement and platform launch:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric Category\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003ctd\u003eValue\/Range\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eExclusivity Term\u003c\/td\u003e\n\u003ctd\u003eLicensing Agreement Duration\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClient Acquisition Cost Reduction (Target)\u003c\/td\u003e\n\u003ctd\u003ePercentage Savings\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e50% - 90%\u003c\/strong\u003e or \u003cstrong\u003e90% - 98%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClient Acquisition Cost (New)\u003c\/td\u003e\n\u003ctd\u003eCost Per Targeted Outreach\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.50 - $5.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClient Acquisition Cost (Traditional)\u003c\/td\u003e\n\u003ctd\u003eCost Per New Client\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$80 - $400\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQualified Lead Generation Cost\u003c\/td\u003e\n\u003ctd\u003eCost Per Pet Parent\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Opportunity\u003c\/td\u003e\n\u003ctd\u003eUS Veterinary AI Market Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.9 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAddressable Market\u003c\/td\u003e\n\u003ctd\u003eUS Veterinary Clinics\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e30,000+\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTechnology Components\u003c\/td\u003e\n\u003ctd\u003ePatent-Pending Innovations\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTechnology Components\u003c\/td\u003e\n\u003ctd\u003eSpecialized AI Agents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Performance (Pre-Launch)\u003c\/td\u003e\n\u003ctd\u003eRecord Fiscal 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.13 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Performance (Pre-Launch)\u003c\/td\u003e\n\u003ctd\u003eQ1 FY2026 Revenue Growth\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e141%\u003c\/strong\u003e Year-over-Year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSaaS Model Projection\u003c\/td\u003e\n\u003ctd\u003eGross Margins\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e80% - 90%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic Investment Component\u003c\/td\u003e\n\u003ctd\u003eRestricted Shares Issued\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe platform's capabilities are supported by:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe AgenticPet AI Framework powering the B2B veterinary-practice platform.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eFive patent-pending innovations protecting core functionality, including distributed agent-certification systems and privacy-preserving health-data synthesis.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eExisting distribution capability through relationships with 1,000+ veterinary clinics.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eProjected revenue streams from B2B subscriptions, lead-generation fees, and premium features.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePetVivo Holdings, Inc. (PETV) - VRIO Analysis: 4. Established US Distributor Network\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eDistributor sales accounted for \u003cstrong\u003e75%\u003c\/strong\u003e of total revenues in Q2 fiscal 2026, totaling \u003cstrong\u003e$237,000\u003c\/strong\u003e. Total revenues for Q2 fiscal 2026 were \u003cstrong\u003e$303,000\u003c\/strong\u003e. Gross profit for the quarter totaled \u003cstrong\u003e$220,000\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ2 Fiscal 2026 Amount\u003c\/th\u003e\n\u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$303,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributor Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$237,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e75%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$220,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e72.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe network is established across all \u003cstrong\u003e50\u003c\/strong\u003e states for key products. The lead product, Spring with OsteoCushion™ Technology, has been used by more than \u003cstrong\u003e1,200\u003c\/strong\u003e veterinary clinics across all \u003cstrong\u003e50\u003c\/strong\u003e states since its late 2021 introduction.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eCompetitors can sign the same major animal health distributors over time.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe company successfully leveraged this channel for \u003cstrong\u003e35%\u003c\/strong\u003e growth in distributor sales in Q2 fiscal 2026 compared to the same year-ago quarter. The company engaged \u003cstrong\u003eadditional distributors\u003c\/strong\u003e during and subsequent to the quarter to further domestic and international expansion.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDistributor sales increased \u003cstrong\u003e35%\u003c\/strong\u003e in Q2 fiscal 2026 over the prior year period.\u003c\/li\u003e\n\u003cli\u003eTotal revenues for Q2 fiscal 2026 increased \u003cstrong\u003e51%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eThe company engaged \u003cstrong\u003eadditional distributors\u003c\/strong\u003e during and subsequent to the quarter for expansion.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eNone, it is a necessary parity resource.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePetVivo Holdings, Inc. (PETV) - VRIO Analysis: 5. International Market Access Footprint\n\u003c\/h2\u003e\n\u003cp\u003eThe international market access footprint provides a strategic layer of diversification beyond the domestic United States operations.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eLaunched operations include Mexico and the United Kingdom, with Canada and the European Union targeted for \u003cstrong\u003e2026\u003c\/strong\u003e. The UK market alone is reported to exceed \u003cstrong\u003e$2.6 billion\u003c\/strong\u003e with a \u003cstrong\u003e7.8% CAGR\u003c\/strong\u003e, while the Mexican veterinary healthcare market is projected to grow at an \u003cstrong\u003e11% CAGR\u003c\/strong\u003e, anticipated to reach approximately \u003cstrong\u003e$2.4 billion\u003c\/strong\u003e within six years. The overall Mexican market size is estimated at more than \u003cstrong\u003e$16.56 billion\u003c\/strong\u003e today.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003cth\u003eCurrent Estimated Size (USD)\u003c\/th\u003e\n\u003cth\u003eProjected CAGR\u003c\/th\u003e\n\u003cth\u003eTimeframe\/Notes\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnited Kingdom (Veterinary)\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e$2.6 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNew distributor, Nupsila Group, operates here.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMexico (Veterinary Healthcare)\u003c\/td\u003e\n\u003ctd\u003eProjected to reach \u003cstrong\u003e$2.4 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eWithin the next six years.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMexico (Overall Market)\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e$16.56 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eProjected to reach \u003cstrong\u003e$34.8 billion\u003c\/strong\u003e by \u003cstrong\u003e2033\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eSecuring distribution in Mexico and the UK by late \u003cstrong\u003e2025\u003c\/strong\u003e positions the company ahead of many peers at this stage of development. The domestic U.S. distributor network sales for Fiscal Q2 2026 (ending September 30, 2025) reached \u003cstrong\u003e$237,000\u003c\/strong\u003e, representing \u003cstrong\u003e75%\u003c\/strong\u003e of total revenues for that quarter.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe imitability of this footprint is assessed as moderate due to the inherent time and capital investment required to navigate foreign regulatory hurdles and establish new, effective distributor relationships.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe company demonstrates active organization toward this goal, evidenced by the reported financial performance and expansion activities. Fiscal Q2 2026 revenues totaled \u003cstrong\u003e$303,000\u003c\/strong\u003e, marking a \u003cstrong\u003e51%\u003c\/strong\u003e year-over-year increase, with first-half revenue exceeding \u003cstrong\u003e$600,000\u003c\/strong\u003e, up \u003cstrong\u003e85%\u003c\/strong\u003e year-over-year. Gross profit for Q2 2026 was \u003cstrong\u003e$220,000\u003c\/strong\u003e, representing \u003cstrong\u003e72.6%\u003c\/strong\u003e of revenues.\u003c\/p\u003e\n\n\u003cp\u003eKey operational metrics supporting international commercialization efforts include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eFiscal Q2 2026 Revenue: \u003cstrong\u003e$303,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eFiscal Q2 2026 Gross Profit Margin: \u003cstrong\u003e72.6%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eCash balance as of September 30, 2025: \u003cstrong\u003e$768,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eTotal Liabilities as of September 30, 2025: Reduced by \u003cstrong\u003e79%\u003c\/strong\u003e to \u003cstrong\u003e$1.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe resulting competitive advantage from international expansion is considered temporary, as global market penetration is a standard strategic objective for growing firms in the animal health sector.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePetVivo Holdings, Inc. (PETV) - VRIO Analysis: 6. High Gross Profit Margin Capability\n\u003c\/h2\u003e\n\u003cp\u003e\nThe capability for high gross profit margins is a significant element in PetVivo Holdings, Inc.'s financial structure, supporting operations despite ongoing operating losses.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHistorical High Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e89.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 Fiscal 2025 Gross Margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit (Q3 FY2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$522,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOn revenues of $583,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin (Latest Reported)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e72.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 Fiscal 2026 Gross Margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit (Q2 FY2026)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$220,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOn revenues of $303,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrevious Quarter Margin (Q1 FY2026)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e63.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\nValue: Historically high margins, like \u003cstrong\u003e89.5%\u003c\/strong\u003e in Q3 fiscal 2025, allow for significant reinvestment despite operating losses. Q2 fiscal 2026 margin was \u003cstrong\u003e72.6%\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\nRarity: The high margin on Spryng is rare, though the introduction of PrecisePRP slightly diluted it in Q2 2025. The Q2 Fiscal 2026 margin of 72.6% was a decrease from \u003cstrong\u003e89.5%\u003c\/strong\u003e in the same year-ago quarter (Q2 FY2025).\n\u003c\/p\u003e\n\u003cp\u003e\nImitability: Difficult for commodity products, but process efficiency can be copied by well-run competitors.\n\u003c\/p\u003e\n\u003cp\u003e\nOrganization: Management is focused on cost control, as seen by the \u003cstrong\u003e79%\u003c\/strong\u003e reduction in total liabilities to \u003cstrong\u003e$1.1 million\u003c\/strong\u003e at September 30, 2025, from $5.1 million at March 31, 2025.\n\u003c\/p\u003e\n\u003cp\u003e\nThe liability reduction was primarily due to:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nExtinguishment of derivative liabilities related to convertible notes.\n\u003c\/li\u003e\n\u003cli\u003e\nReduction in accounts payables due to settlement payments with trade vendors.\n\u003c\/li\u003e\n\u003cli\u003e\nConversion of convertible promissory notes to common stock.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nCompetitive Advantage: Temporary, as margin pressure is a constant threat in medical device sales.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePetVivo Holdings, Inc. (PETV) - VRIO Analysis: 7. Capital-Efficient Product Commercialization Strategy\n\u003c\/h2\u003e\n\n\u003cp\u003eThe strategy centers on leveraging human therapy science for animal applications, aiming for an accelerated timeline to revenue characteristic of medical devices versus pharmaceuticals.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eFocuses on medical devices, which have an accelerated timeline to revenue compared to more stringently regulated pharmaceuticals. The lead product, SPRYNG™ with OsteoCushion™ Technology, is a veterinarian-administered, intraarticular injection for managing lameness and joint afflictions in dogs and horses.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eLeveraging human therapy science for animal applications is a known, but not universally adopted, efficient strategy. The company protects its technology with a portfolio of twenty-one patents covering biomaterials, products, production processes, and methods of use.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eModerate. Competitors can adopt a similar focus, but PetVivo has a head start with its current portfolio. The commercialization success is evidenced by recent revenue figures.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePeriod\u003c\/th\u003e\n\u003cth\u003eProduct\/Channel\u003c\/th\u003e\n\u003cth\u003eRevenue Amount\u003c\/th\u003e\n\u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 FY2026 (Ended Sep 30, 2025)\u003c\/td\u003e\n\u003ctd\u003eDistributor Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$237,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e75%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 FY2026 (Ended Sep 30, 2025)\u003c\/td\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$303,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3 Months Ended Dec 31, 2023\u003c\/td\u003e\n\u003ctd\u003eMWI Sales (Distributor)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$439,922\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e73.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3 Months Ended Dec 31, 2023\u003c\/td\u003e\n\u003ctd\u003eCovetrus Sales (Distributor)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$106,074\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3 Months Ended Dec 31, 2023\u003c\/td\u003e\n\u003ctd\u003eVeterinary Clinic Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$49,265\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3 Months Ended Dec 31, 2023\u003c\/td\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$595,891\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThis strategy underpins the entire business model, guiding product selection and development focus. Financial metrics reflect this focus on commercial scaling:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGross profit for Q2 FY2026 was \u003cstrong\u003e$220,000\u003c\/strong\u003e, with a gross margin of \u003cstrong\u003e72.6%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Liabilities decreased 79% to \u003cstrong\u003e$1.1 million\u003c\/strong\u003e as of September 30, 2025, from \u003cstrong\u003e$5.1 million\u003c\/strong\u003e at March 31, 2025.\u003c\/li\u003e\n\u003cli\u003eCash totaled \u003cstrong\u003e$768,000\u003c\/strong\u003e on September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eTotal Assets were \u003cstrong\u003e$3,186,744\u003c\/strong\u003e at September 30, 2024.\u003c\/li\u003e\n\u003cli\u003eOperating Loss for Q2 FY2026 increased 12% to \u003cstrong\u003e$2.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eTemporary, as it is a strategic choice rather than a unique, protected asset. The company noted that Spryng was used by over 450 veterinarian clinics in 47 states in the United States as of Q1 FY2024.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePetVivo Holdings, Inc. (PETV) - VRIO Analysis: 8. Deleveraged Balance Sheet Structure\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eTotal liabilities decreased by \u003cstrong\u003e79%\u003c\/strong\u003e to \u003cstrong\u003e$1.1 million\u003c\/strong\u003e as of September 30, 2025, from \u003cstrong\u003e$5.1 million\u003c\/strong\u003e at March 31, 2025. The cash balance improved to \u003cstrong\u003e$768,000\u003c\/strong\u003e on September 30, 2025, compared to \u003cstrong\u003e$228,000\u003c\/strong\u003e on March 31, 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eBalance Sheet Metric\u003c\/td\u003e\n\u003ctd\u003eAmount as of September 30, 2025\u003c\/td\u003e\n\u003ctd\u003eAmount as of March 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Liabilities (in millions USD)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.1\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Balance (in thousands USD)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$768\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$228\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eA \u003cstrong\u003e79%\u003c\/strong\u003e reduction in total liabilities over a six-month period, moving from \u003cstrong\u003e$5.1 million\u003c\/strong\u003e to \u003cstrong\u003e$1.1 million\u003c\/strong\u003e, represents a massive, rapid deleveraging event that significantly reduces immediate financial risk exposure.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eLow, as the deleveraging required specific, large-scale financing and settlement events, including the extinguishment of derivative liabilities and note conversions, which are not easily replicated.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe finance team executed a major cleanup, resulting in the reported balance sheet structure. The cash balance increased to \u003cstrong\u003e$768,000\u003c\/strong\u003e by September 30, 2025, primarily due to financing activities.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eExtinguishment of derivative liabilities related to convertible notes.\u003c\/li\u003e\n\u003cli\u003eReduction in accounts payables due to settlement payments with trade vendors.\u003c\/li\u003e\n\u003cli\u003eConversion of convertible promissory notes to common stock on September 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary. The immediate benefit of a cleaner balance sheet is substantial, but it reflects the successful execution of a past financial restructuring rather than an ongoing, sustainable operational advantage.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePetVivo Holdings, Inc. (PETV) - VRIO Analysis: 9. Direct Veterinary Clinic Relationships\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Over \u003cstrong\u003e1,200\u003c\/strong\u003e clinics across all 50 states use Spryng, creating a direct channel for product adoption and, crucially, a data source for the new AI platform.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Deep, established relationships with a large number of clinics, specifically exceeding \u003cstrong\u003e1,200\u003c\/strong\u003e users, are valuable for product adoption and data flow.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors can build relationships, but PetVivo’s existing installed base of over \u003cstrong\u003e1,200\u003c\/strong\u003e clinics is a head start.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The AI partnership, an exclusive 10-year white-label licensing agreement for Agentic Pet AI technology, is designed to exploit these relationships by automatically flowing pet health data to participating vets.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as the AI integration is the key differentiator that must prove its worth quickly.\u003c\/p\u003e\n\u003cp\u003eClinic Adoption and Distribution Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Period Reference\u003c\/th\u003e\n\u003cth\u003eSource\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpryng Used By Clinics\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e1,200\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025 (Q2 FY2026)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStates with Clinic Presence\u003c\/td\u003e\n\u003ctd\u003eAll \u003cstrong\u003e50\u003c\/strong\u003e states\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025 (Q2 FY2026)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 FY2026 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$303,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarter ending September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 FY2026 Distributor Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$237,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRepresenting \u003cstrong\u003e75%\u003c\/strong\u003e of total revenues\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOperational Highlights Related to Clinic Network:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRevenues for the second quarter of fiscal 2026 ending September 30, 2025, increased \u003cstrong\u003e51%\u003c\/strong\u003e to \u003cstrong\u003e$303,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDistributor sales increased \u003cstrong\u003e35%\u003c\/strong\u003e to \u003cstrong\u003e$237,000\u003c\/strong\u003e in Q2 FY2026.\u003c\/li\u003e\n\u003cli\u003eThe company has a VGP agreement to actively promote Spryng to its member network of more than \u003cstrong\u003e7,300\u003c\/strong\u003e veterinary clinic members.\u003c\/li\u003e\n\u003cli\u003eThe third and fourth quarters have traditionally been the strongest for the company, typically driving greater product awareness and new orders.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: The 13-week cash flow projection incorporating the Q3 revenue forecast is not publicly available; however, the latest reported revenue for Q2 FY2026 (ending September 30, 2025) was \u003cstrong\u003e$303,000\u003c\/strong\u003e. Management anticipates another year of record growth for the full fiscal year ending March 31, 2026.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516229673109,"sku":"petv-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/petv-vrio-analysis.png?v=1740205690","url":"https:\/\/dcf-model.com\/fr\/products\/petv-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}